Target Name: ZNF410
NCBI ID: G57862
Review Report on ZNF410 Target / Biomarker Content of Review Report on ZNF410 Target / Biomarker
ZNF410
Other Name(s): APA-1 | zinc finger protein APA-1 | clones 23667 and 23775 zinc finger protein | Zinc finger protein 410, transcript variant 1 | Clones 23667 and 23775 zinc finger protein | Zinc finger protein 410 (isoform a) | ZN410_HUMAN | Another partner for ARF 1 | Zinc finger protein APA-1 | another partner for ARF 1 | ZNF410 variant 1 | APA1 | zinc finger protein 410 | Zinc finger protein 410

Understanding ZNF410: A Potential Drug Target Or Biomarker

ZNF410 (APA-1) is a protein that is expressed in various tissues of the body, including the brain. It is a key regulator of cell proliferation and has been linked to a number of neurological and psychiatric disorders. As a result, ZNF410 has generated a lot of interest as a potential drug target or biomarker.

The story of ZNF410 began in the early 1990s when a team of researchers led by Dr. David S. Moore at the University of California, San Diego identified the protein as a potential regulator of cell proliferation. They found that when the protein was expressed in cell culture, it activated genes that were involved in cell growth and division.

Over the years, more research has confirmed the role of ZNF410 in cell proliferation and the development of various diseases. For example, studies have shown that when ZNF410 is expressed in cancer cells, it promotes cell growth and the development of cancer. Similarly, ZNF410 has also been linked to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's.

Despite these promising findings, ZNF410 has not yet been approved as a drug target or biomarker. One of the main challenges in studying this protein is its complex structure. ZNF410 is a large protein that contains multiple domains, including an N-terminal transmembrane domain, a nuclear localization domain, and a C-terminal T-cell factor-response domain. These domains give ZNF410 a highly complex structure that is difficult to study.

In addition, the lack of human studies with ZNF410 has made it difficult to fully understand its role in disease. While there are some studies in animals, there are still limited data on its effects in humans. This lack of human data has made it difficult for companies to develop ZNF410-based drugs or biomarkers, as they have not been able to conduct clinical trials to test the safety and efficacy of these products in humans.

Despite these challenges, the study of ZNF410 is still an exciting area of research. The potential of this protein as a drug target or biomarker is significant. If ZNF410 is proven to be involved in the development of certain diseases, it could lead to the development of new treatments that could improve the lives of people with these conditions.

In conclusion, ZNF410 is a protein that has generated a lot of interest as a potential drug target or biomarker due to its role in cell proliferation and the development of various neurological and psychiatric disorders. While there are still many challenges to be overcome, the study of ZNF410 is an exciting area of research that has the potential to improve the lives of people with these conditions.

Protein Name: Zinc Finger Protein 410

Functions: Transcription factor that binds to the sequence motif 5'-CATCCCATAATA-3', and is specifically required to silence expression of fetal hemoglobin in adult erythroid cells (PubMed:33859416, PubMed:33301730). Prevents expression of fetal hemoglobin genes HBG1 and HBG2 through CHD4: acts as a direct transcriptional activator of CHD4, a central component of the NuRD complex that represses transcription of fetal hemoglobin genes HBG1 and HBG2 in erythroid cells (PubMed:33859416, PubMed:33301730). May also activate transcription of matrix-remodeling genes such as MMP1 during fibroblast senescence (PubMed:12370286). May activate transcription of the gap junction gene GJC1, perhaps in response to increasing glucose (PubMed:30078215). However, recent studies suggest that ZNF410 is dedicated to regulate expression of a single gene: CHD4 (PubMed:33859416, PubMed:33301730)

The "ZNF410 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF410 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF414 | ZNF415 | ZNF416 | ZNF417 | ZNF418 | ZNF419 | ZNF420 | ZNF423 | ZNF425 | ZNF426 | ZNF428 | ZNF429 | ZNF43 | ZNF430 | ZNF431 | ZNF432 | ZNF433 | ZNF433-AS1 | ZNF436 | ZNF436-AS1 | ZNF438 | ZNF439 | ZNF44 | ZNF440 | ZNF441 | ZNF442 | ZNF443 | ZNF444 | ZNF445 | ZNF446 | ZNF449 | ZNF45 | ZNF451 | ZNF454 | ZNF460 | ZNF461 | ZNF462 | ZNF467 | ZNF468 | ZNF469 | ZNF470 | ZNF471 | ZNF473 | ZNF473CR | ZNF479 | ZNF48 | ZNF480 | ZNF483 | ZNF484 | ZNF485 | ZNF486 | ZNF487 | ZNF488 | ZNF490 | ZNF491 | ZNF492 | ZNF493 | ZNF496 | ZNF497 | ZNF497-AS1 | ZNF500 | ZNF501 | ZNF502 | ZNF503 | ZNF503-AS1 | ZNF503-AS2 | ZNF506 | ZNF507 | ZNF510 | ZNF511 | ZNF512 | ZNF512B | ZNF513 | ZNF514 | ZNF516 | ZNF516-DT | ZNF517 | ZNF518A | ZNF518B | ZNF519 | ZNF519P3 | ZNF521 | ZNF524 | ZNF525 | ZNF526 | ZNF527 | ZNF528 | ZNF528-AS1 | ZNF529 | ZNF529-AS1 | ZNF530 | ZNF532 | ZNF534 | ZNF536 | ZNF540 | ZNF541 | ZNF542P | ZNF543 | ZNF544 | ZNF546